CellCura ASA (Oslo Axess: CELL), announces its results for the fourth quarter, 2013. A presentation will be held at 3 PM today at the Company's office at Vika Atrium, Munkedamsveien 45 A, 5th floor, Oslo.

Highlights from the quarter and subsequent period:

  • The installation of the first ART Lab Solution in our home market has now been completed and the workstation is in operational use. This is a strategically important installation that we have good reasons to expect will contribute to a broader footprint in the local market, also in the short-term.

  • In October 2013 CellCura applied for a research grant through the "Programme for User-Driven Research Based Innovation" sponsored by The Norwegian Research Council.  CellCura is proud to announce that the Company's CASPAR project was one of the projects that were granted funding.

  • A clinical evaluation of our Protein-Free IUI (Intra Uterine Insemination) media products have been completed in Q4 with very good results. The purpose of the testing has been to evaluate the potential of test materials to cause irritation on the exposed part of the body, and to evaluate the allergenic potential or sensitizing capacity of the test article. Our Protein-Free IUI media now meets the requirements of the ISO 10993-10 guidelines.

Quarterly report and presentation attached.

Oslo, 27 February 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
Phone: + 47 911 08 693

CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology.

CellCura is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker:CELL).

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
distributed by